In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.

The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...

Life sciences trade association BioNJ has announced the election of its 2025 Officers and Board Members in concert with BioNJ ...

Tennessee IT specialist Bradley Dawson gets life in prison for the murder of pharmacist wife Christe Chen on their honeymoon ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

Investors with a lot of money to spend have taken a bearish stance on Teva Pharmaceutical Indus (NYSE:TEVA). And retail traders should know. We noticed this today when the trades showed up on ...